CD274 and esophageal squamous cell carcinoma: Since immunotherapy combined with chemotherapy has been introduced as a first-line treatment for ESCC, this study sought to identify an optimal inflammatory biomarker for predicting the prognosis of previously untreated ESCC patients who received PD-1/PD-L1 ICIs plus chemotherapy.